An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy

Grünwald, Viktor;Karakiewicz, Pierre I.;Bavbek, Sevil E.;Miller, Kurt;Bodrogi, István;et.al.
(2012) European Journal of Cancer — Vol. 48, n° 3, p. 324-332 (2012)

Files

pdfdocument.pdf
  • Restricted Access
  • Adobe PDF
  • 256.91 KB
Request a copy

Details

Authors
  • Grünwald, Viktor
    Author
  • Karakiewicz, Pierre I.
    Author
  • Bavbek, Sevil E.
    Author
  • Miller, Kurt
    Author
  • Machiels, Jean-PascalUCLouvain
    Author
  • Bodrogi, István
    Author
Show more
Abstract
BACKGROUND AND OBJECTIVES: The RECORD-1 trial established the clinical benefit of everolimus in patients with metastatic renal cell carcinoma (mRCC) after failure of initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy. The REACT (RAD001 Expanded Access Clinical Trial in RCC) study was initiated to address an unmet medical need by providing everolimus prior to commercial availability, and also to further assess the safety and efficacy of everolimus in patients with VEGFr-TKI-refractory mRCC. PATIENTS AND METHODS: REACT (Clinicaltrials.gov: NCT00655252) was a global, open-label, expanded-access programme in patients with mRCC who were intolerant of, or who had progressed on or after stopping treatment with, any available VEGFr-TKI therapy. Patients received everolimus 10mg once daily, with dose and schedule modifications allowed for toxicity. Patients were closely monitored for the development of serious and grades 3/4 adverse events (AEs). Response was assessed by RECIST every 3months for the first year and every 6months thereafter. RESULTS: A total of 1367 patients were enroled. Safety findings and tumour responses were consistent with those observed in RECORD-1, with no new safety issues identified. The most commonly reported serious AEs were dyspnoea (5.0%), pneumonia (4.7%) and anaemia (4.1%), and the most commonly reported grades 3/4 AEs were anaemia (13.4%), fatigue (6.7%) and dyspnoea (6.5%). Best overall response was stable disease in 51.6% and partial response in 1.7% of patients. Median everolimus treatment duration was 14weeks. CONCLUSION: Everolimus is well tolerated in patients with mRCC and demonstrates a favourable risk-benefit ratio.
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Grünwald, V., Karakiewicz, P. I., Bavbek, S. E., Miller, K., Machiels, J.-P., Lee, S.-H., Larkin, J., Bono, P., Rha, S. Y., Castellano, D., Blank, C. U., Knox, J. J., Hawkins, R., Anak, O., Rosamilia, M., Booth, J., Pirotta, N., & Bodrogi, I. (2012). An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. European Journal of Cancer, 48(3), 324-332. https://doi.org/10.1016/j.ejca.2011.06.054 (Original work published 2012)